Attovia Therapeutics Inc.
ATTO | NASDAQ
$21.30
-$0.84 (-3.79%)
At close: Sep 21, 2026, 4:00 PM ET
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q1 2025 Mar 30, 2025 |
|---|---|---|---|
Net Income | -39.34M | -18.66M | -15.42M |
Depreciation & Amortization | 488K | 242K | 143K |
Stock-Based Compensation | n/a | n/a | n/a |
Other Working Capital | -1.06M | -428K | -158K |
Other Non-Cash Items | 1.83M | 814K | 1.12M |
Deferred Income Tax | n/a | n/a | n/a |
Change in Working Capital | 2.1M | -541K | 28K |
Operating Cash Flow | -34.93M | -18.14M | -14.13M |
Capital Expenditures | -361K | -288K | -1.79M |
Cash Acquisitions | n/a | n/a | n/a |
Purchase of Investments | -48.17M | -20.23M | -45.5M |
Sales Maturities Of Investments | 77.9M | 43M | 18M |
Other Investing Acitivies | n/a | n/a | n/a |
Investing Cash Flow | 29.37M | 22.49M | -29.29M |
Debt Repayment | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a |
Financial Cash Flow | -1.8M | -1.24M | 141.89M |
Net Cash Flow | 32.83M | 43.3M | n/a |
Free Cash Flow | -35.29M | -18.43M | -15.92M |
Adj. Free Cash Flow | -35.29M | -18.43M | -15.92M |
Maintenance CapEx | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a |
Owner Earnings | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove ATTO